Treatment

Treating polycystic kidney disease involves dealing with the following signs, symptoms and complications in their early stages:

  • High blood pressure. Controlling high blood pressure can delay the progression of the disease and slow further kidney damage. Combining a low-sodium, low-fat diet that's moderate in protein and calorie content with not smoking, increasing exercise and reducing stress may help control high blood pressure.

    However, medications are usually needed to control high blood pressure. Medications called angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are often used to control high blood pressure.

  • Pain. You might be able to control the pain of polycystic kidney disease with over-the-counter medications containing acetaminophen. For some people, however, the pain is more severe and constant. In rare cases, your doctor might recommend surgery to remove cysts if they're large enough to cause pressure and pain.
  • Bladder or kidney infections. Prompt treatment of infections with antibiotics is necessary to prevent kidney damage.
  • Blood in the urine. You'll need to drink lots of fluids, preferably plain water, as soon as you notice blood in your urine to dilute the urine. Dilution might help prevent obstructive clots from forming in your urinary tract.
  • Kidney failure. If your kidneys lose their ability to remove waste products and extra fluids from your blood, you'll eventually need either dialysis or a kidney transplant.
  • Aneurysms. If you have polycystic kidney disease and a family history of ruptured brain (intracranial) aneurysms, your doctor may recommend regular screening for intracranial aneurysms.

If an aneurysm is discovered, surgical clipping of the aneurysm to reduce the risk of bleeding may be an option, depending on its size. Nonsurgical treatment of small aneurysms may involve controlling high blood pressure and high blood cholesterol, as well as quitting smoking.

July 13, 2017
References
  1. Polycystic kidney disease. National Kidney and Urologic Diseases Information Clearinghouse. http://kidney.niddk.nih.gov/kudiseases/pubs/polycystic/. Accessed March 11, 2017.
  2. Chapman AB, et al. Course and treatment of autosomal dominant polycystic kidney disease. https://www.uptodate.com/home. Accessed March 11, 2017.
  3. Polycystic kidney disease. American Kidney Fund. http://www.kidneyfund.org/kidney-disease/other-kidney-conditions/polycystic-kidney-disease.html?&gclid=Cj0KEQiA3Y7GBRD29f-7kYuO1-ABEiQAodAvwGAsS7ELsM8hNXkbCPt3pE8hsRp-kijSf4UAs-ZmPVgaArPQ8P8HAQ. Accessed March 11, 2017.
  4. Bennett WM, et al. Extrarenal manifestations of autosomal dominant polycystic kidney disease. https://www.uptodate.com/home. Accessed March 11, 2017.
  5. Polycystic kidney disease. National Kidney Foundation. https://www.kidney.org/atoz/content/polycystic. Accessed March 11, 2017.
  6. Torres VE, et al. Diagnosis and screening for autosomal dominant polycystic kidney disease. https://www.uptodate.com/home. Accessed March 11, 2017.
  7. Albert CM, et al. Autosomal dominant polycystic kidney disease: The changing face of clinical management. The Lancet. 2015;385:1993.
  8. Rossetti S, et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. Journal of the American Society of Nephrology. 2012;23:915.
  9. Torres VE, et al. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. Journal of the American Society of Nephrology. 2014; 25:18.
  10. Shoaf SE, et al. Pharmacokinetics and pharmacodynamics of Tolvaptan in autosomal dominat polycystic kidney disease: Phase 2 trials for dose selection in the pivotal phase 3 trial. The Journal of Clinical Pharmacology. In press. Accessed March 11, 2017.
  11. Hogan MC, et al. Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years. Nephrology Dialysis Transplantation. 2012;27:3532.
  12. Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Jan. 24, 2017.